This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
by Arpita Dutt
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
Sanofi's Toujeo Meets Key Objective in Head-to-Head Study
by Zacks Equity Research
Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention
by Zacks Equity Research
Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.
Alnylam's RNAi Candidate Gains Breakthrough Therapy Status
by Zacks Equity Research
Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.
Alnylam Starts Rolling NDA Submission for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?
by Zacks Equity Research
Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA
by Zacks Equity Research
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day
by Arpita Dutt
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
by Arpita Dutt
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
by Zacks Equity Research
Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?
by Zacks Equity Research
Investor focus should be on Eylea's performance and uptake of Dupixent when Regeneron Pharmaceuticals (REGN) reports third-quarter results
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.
Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak
by Zacks Equity Research
Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.
BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised
by Zacks Equity Research
BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.
Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong
by Zacks Equity Research
Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.
Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers
by Arpita Dutt
It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.
Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls
by Zacks Equity Research
Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
by Zacks Equity Research
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
Pricing Pressure, Competition Remain Headwinds for Pharma Stocks
by Arpita Dutt
Although the pharma and biotech sectors have rebounded in 2017, drug companies may find it a bit difficult to justify their high prices.
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.